Login
Home
Charts
Search
Watchlist
Products

Virinchi Ltd

VIRINCHI·NSE
14.03+0.21%Wed, 23 Sept '26 15:51

Virinchi Ltd

VIRINCHI
NSE
14.03
+0.21%
|Wed, 23 Sept '26 15:51
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
158Cr
Close
Close Price
14.01
Industry
Industry
IT - Software
PE
Price To Earnings
PS
Price To Sales
0.57
Revenue
Revenue
275Cr
Rev Gr TTM
Revenue Growth TTM
-10.02%
PAT Gr TTM
PAT Growth TTM
-15,615.79%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
737375767482698062776670
Growth YoY
Revenue Growth YoY%
-8.2-8.4-4.2-6.02.413.6-7.75.6-16.8-6.7-4.3-12.1
Expenses
ExpensesCr
504447545056525451515955
Operating Profit
Operating ProfitCr
22292822242717261126715
OPM
OPM%
30.539.937.628.832.432.424.432.717.133.411.321.2
Other Income
Other IncomeCr
104100600010
Interest Expense
Interest ExpenseCr
101111101091098888
Depreciation
DepreciationCr
131412131316141414141413
PBT
PBTCr
058022-13-124-18-6
Tax
TaxCr
-106-11-23323-3-4
PAT
PATCr
162104-40-142-16-2
Growth YoY
PAT Growth YoY%
141.5-6.3-83.2-76.2-88.4-33.1-317.6-64.8-8,141.2-56.9-253.4-667.6
NPM
NPM%
2.07.72.71.40.24.5-6.40.5-22.12.1-23.8-3.0
EPS
EPS
0.20.60.20.10.00.4-0.40.0-1.30.1-1.40.0
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
737375767482698062776670
Growth YoY
Revenue Growth YoY%
-8.2-8.4-4.2-6.02.413.6-7.75.6-16.8-6.7-4.3-12.1
Expenses
ExpensesCr
504447545056525451515955
Operating Profit
Operating ProfitCr
22292822242717261126715
OPM
OPM%
30.539.937.628.832.432.424.432.717.133.411.321.2
Other Income
Other IncomeCr
104100600010
Interest Expense
Interest ExpenseCr
101111101091098888
Depreciation
DepreciationCr
131412131316141414141413
PBT
PBTCr
058022-13-124-18-6
Tax
TaxCr
-106-11-23323-3-4
PAT
PATCr
162104-40-142-16-2
Growth YoY
PAT Growth YoY%
141.5-6.3-83.2-76.2-88.4-33.1-317.6-64.8-8,141.2-56.9-253.4-667.6
NPM
NPM%
2.07.72.71.40.24.5-6.40.5-22.12.1-23.8-3.0
EPS
EPS
0.20.60.20.10.00.4-0.40.0-1.30.1-1.40.0

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
218287341407381354364312300301284275
Growth
Revenue Growth%
57.331.319.119.2-6.3-7.22.8-14.3-3.80.4-5.6-10.0
Expenses
ExpensesCr
187223246287271258264206191212215216
Operating Profit
Operating ProfitCr
31649612011196100106109897059
OPM
OPM%
14.322.328.129.529.027.027.434.036.429.624.521.3
Other Income
Other IncomeCr
2214211345722
Interest Expense
Interest ExpenseCr
31218222232263343393332
Depreciation
DepreciationCr
122533364548485654555656
PBT
PBTCr
1830466646222821172-23-32
Tax
TaxCr
26137-119148424-2
PAT
PATCr
162433594631413130-27-30
Growth
PAT Growth%
95.545.640.078.4-21.1-94.3428.2-9.96.0-96.4-5,757.9-15,615.8
NPM
NPM%
7.48.29.714.512.20.83.94.14.50.2-9.6-10.9
EPS
EPS
4.54.45.89.47.10.31.81.61.50.1-2.5-2.5
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
218287341407381354364312300301284275
Growth
Revenue Growth%
57.331.319.119.2-6.3-7.22.8-14.3-3.80.4-5.6-10.0
Expenses
ExpensesCr
187223246287271258264206191212215216
Operating Profit
Operating ProfitCr
31649612011196100106109897059
OPM
OPM%
14.322.328.129.529.027.027.434.036.429.624.521.3
Other Income
Other IncomeCr
2214211345722
Interest Expense
Interest ExpenseCr
31218222232263343393332
Depreciation
DepreciationCr
122533364548485654555656
PBT
PBTCr
1830466646222821172-23-32
Tax
TaxCr
26137-119148424-2
PAT
PATCr
162433594631413130-27-30
Growth
PAT Growth%
95.545.640.078.4-21.1-94.3428.2-9.96.0-96.4-5,757.9-15,615.8
NPM
NPM%
7.48.29.714.512.20.83.94.14.50.2-9.6-10.9
EPS
EPS
4.54.45.89.47.10.31.81.61.50.1-2.5-2.5

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
182728313337798494103109
Reserves
ReservesCr
106180221281341338292314353373384
Current Liabilities
Current LiabilitiesCr
488311610488100100114137123132
Non Current Liabilities
Non Current LiabilitiesCr
93128122114104212233266260250236
Total Liabilities
Total LiabilitiesCr
264418494535567687703787851847850
Current Assets
Current AssetsCr
8689153148157173195206209183224
Non Current Assets
Non Current AssetsCr
178329341387410514509581642664627
Total Assets
Total AssetsCr
264418494535567687703787851847850
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
182728313337798494103109
Reserves
ReservesCr
106180221281341338292314353373384
Current Liabilities
Current LiabilitiesCr
488311610488100100114137123132
Non Current Liabilities
Non Current LiabilitiesCr
93128122114104212233266260250236
Total Liabilities
Total LiabilitiesCr
264418494535567687703787851847850
Current Assets
Current AssetsCr
8689153148157173195206209183224
Non Current Assets
Non Current AssetsCr
178329341387410514509581642664627
Total Assets
Total AssetsCr
264418494535567687703787851847850

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
237935818550821271168421
Investing Cash Flow
Investing Cash FlowCr
-94-126-51-83-68-154-34-137-114-78-19
Financing Cash Flow
Financing Cash FlowCr
7331141-17115-314-13-19-1
Net Cash Flow
Net Cash FlowCr
2-16-1-101018-6-11-121
Free Cash Flow
Free Cash FlowCr
-70-46-15-317-1250-9352
CFO To PAT
CFO To PAT%
141.2334.2106.6137.6183.51,865.2581.91,002.0863.217,347.4-76.6
CFO To EBITDA
CFO To EBITDA%
73.5123.536.767.577.152.282.4120.0106.794.130.1
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
237935818550821271168421
Investing Cash Flow
Investing Cash FlowCr
-94-126-51-83-68-154-34-137-114-78-19
Financing Cash Flow
Financing Cash FlowCr
7331141-17115-314-13-19-1
Net Cash Flow
Net Cash FlowCr
2-16-1-101018-6-11-121
Free Cash Flow
Free Cash FlowCr
-70-46-15-317-1250-9352
CFO To PAT
CFO To PAT%
141.2334.2106.6137.6183.51,865.2581.91,002.0863.217,347.4-76.6
CFO To EBITDA
CFO To EBITDA%
73.5123.536.767.577.152.282.4120.0106.794.130.1

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5931029125786129463314288214153158
Price To Earnings
Price To Earnings
3.613.18.84.31.947.032.424.321.0297.6
Price To Sales
Price To Sales
0.31.10.80.60.20.41.31.01.00.70.50.6
Price To Book
Price To Book
0.51.51.20.80.20.31.30.80.60.50.30.3
EV To EBITDA
EV To EBITDA
4.67.24.63.42.13.97.05.75.55.64.17.2
Profitability Ratios
Profitability Ratios
GPM
GPM%
99.494.590.687.887.290.889.090.791.986.1
OPM
OPM%
14.322.328.129.529.027.027.434.036.429.624.521.3
NPM
NPM%
7.48.29.714.512.20.83.94.14.50.2-9.6-10.9
ROCE
ROCE%
9.111.215.618.612.88.48.47.57.85.41.61.6
ROE
ROE%
13.111.413.318.912.40.73.83.23.00.1-5.6-5.6
ROA
ROA%
6.15.76.711.08.20.42.01.61.60.1-3.2-3.2
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5931029125786129463314288214153158
Price To Earnings
Price To Earnings
3.613.18.84.31.947.032.424.321.0297.6
Price To Sales
Price To Sales
0.31.10.80.60.20.41.31.01.00.70.50.6
Price To Book
Price To Book
0.51.51.20.80.20.31.30.80.60.50.30.3
EV To EBITDA
EV To EBITDA
4.67.24.63.42.13.97.05.75.55.64.17.2
Profitability Ratios
Profitability Ratios
GPM
GPM%
99.494.590.687.887.290.889.090.791.986.1
OPM
OPM%
14.322.328.129.529.027.027.434.036.429.624.521.3
NPM
NPM%
7.48.29.714.512.20.83.94.14.50.2-9.6-10.9
ROCE
ROCE%
9.111.215.618.612.88.48.47.57.85.41.61.6
ROE
ROE%
13.111.413.318.912.40.73.83.23.00.1-5.6-5.6
ROA
ROA%
6.15.76.711.08.20.42.01.61.60.1-3.2-3.2
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Virinchi Ltd is a technology-led business-solutions provider that began in 1990 as a focused IT company and has since evolved into a multi-vertical enterprise spanning US fintech, Indian digital credit, and multi-specialty hospitals in Hyderabad. Founded by first-generation IIT/IIM entrepreneurs and headquartered in Hyderabad, the company follows a deliberate “Cash Cow & Sunrise Businesses” approach-it uses the steady annuity surpluses from one business to fund the launch and growth of the next, with the ultimate intent of separately listing each vertical to unlock shareholder value. That recurring logic of bundling initiatives to build scale and then unbundling them explains why a single listed entity today houses a market-leading US lending platform, an Indian credit app, and a chain of hospitals. # Business segments Five engines at different stages-a US fintech cash cow, an Indian credit challenger, a healthcare network scaling fast, and two IT services engines that underpin the rest-each built with the cash flows of the one before. ## 1. QFund: the technology backbone for America’s subprime lenders **A mission-critical SaaS platform that runs the entire loan lifecycle for the largest alternative-finance companies in the US, earning a fee on every transaction-not on the loans themselves.** - **Paid per transaction, not per loan** - QFund operates on a pay-per-use model, charging lenders on a per-transaction, per-point-of-sale, or per-licensed-user basis, so its revenue rises directly with its clients’ lending activity rather than with interest income. - **The platform does everything** - it handles loan origination, eligibility checks with credit-rating and fraud agencies, its own machine-learning underwriting, disbursement, and post-disbursement servicing including collections when borrowers miss payments or declare bankruptcy, which makes it deeply embedded in a lender’s daily operations. - **A moat built on scale and stickiness** - the platform has processed over $16 billion in transaction value, served more than 12 million unique borrowers, and counts 12 of the top 20 US alternative-finance companies as clients, with an average engagement of at least five years per customer; the next-largest competitor is roughly 40% of Virinchi’s size, so rivals cannot compete on scale or cost. - **Regulation keeps the barriers high** - the US alternative-finance industry is heavily regulated and continuously evolving under CFPB rules, and large Indian IT firms stay away from these small, niche assignments with a steep learning curve, leaving QFund with a defensible position. - **A two-decade data advantage** - the platform has sanctioned 29 million loans and processed nearly 63 million payments, generating enough data to achieve over 90% predictive accuracy in its machine-learning credit-scoring and default-prediction models, which makes its underwriting tools increasingly hard to replicate. ## 2. vCard: a credit card built on India’s UPI rails **India’s first mobile-based credit platform that plugs into the country’s 150-million-strong UPI acceptance network to distribute small-ticket credit to people the traditional card industry ignores.** - **Credit without a credit score** - vCard uses a machine-learning-based multiparametric model to underwrite customers who have no CIBIL history, enabling instant credit decisions based on a broader profile rather than a traditional bureau score. - **Rides on rails it doesn’t own** - the platform is acceptance-network-independent, meaning it uses the existing UPI infrastructure for transaction closure instead of building its own merchant network, which is how it reaches a base of 150 million UPI acceptance points without the cost of a physical card network. - **Two products, one platform** - it offers a co-branded credit card with banks (limits of ₹1-5 lakh) and a revolving credit line from NBFCs (limits of ₹15,000-45,000 with an interest-free sub-limit of up to ₹5,000 per month), both managed through the same digitised loan-lifecycle system covering origination, disbursals, collections, and regulatory reporting. - **Origination costs cut by a factor of 100** - the digital onboarding process, which works through channels like Facebook and WhatsApp, brought the cost of acquiring a customer down to roughly one-hundredth of what a traditional credit card costs to originate, making small-ticket lending economically viable. - **A turnkey model for banks** - Virinchi can operate the entire credit programme for a partner bank or NBFC, handling client acquisition, KYC, loan disbursements, servicing, and collections, which is how it built cumulative disbursements of more than $50 million across its credit-line and banking partnerships. ## 3. Virinchi People’s Hospital: a super-specialty chain built on leased real estate **A 600-bed multi-specialty hospital network in Hyderabad that keeps its balance sheet light by leasing rather than owning, and staffs its wards with salaried doctors instead of commission-based consultants.** - **Leased, not built from scratch** - the flagship 400-bed hospital in Banjara Hills was created by converting a super mall under a 30-year lease, and the company achieved a commissioning cost of ₹45 lakh per bed against an industry average of ₹60 lakh, completing a leased brownfield hospital in just 14 months. - **Doctors on salary, not commission** - the full-time senior medical team is remunerated on a fixed-fee model rather than a share of patient billing, which aligns clinical incentives with patient outcomes rather than procedure volumes. - **A paperless, mobile-only operation** - all front-office, nursing, and ward processes run on electronic tablets through a proprietary EMR platform called vHealth, with a CEO dashboard providing real-time analytics across the chain. - **Super-specialty focus with teaching-hospital status** - the flagship facility has 11 modular operating theatres, 140 ICU beds, and over 45 specialties concentrated on cardiology, orthopaedics, nephrology, neurology, emergency, cancer, and transplant care, and it admits NEET-qualified students for postgraduate degree courses. - **Expansion through a hub-and-spoke model** - a 100-bed radiation-oncology block is under construction contiguous to the flagship, and a 300-bed facility in Vizag Health City is planned on a 30-year lease, with a path to 1,100 total beds across the network. ## 4. KSoft: the IT-services engine that feeds the group **A consulting and technology-services division that builds enterprise applications and runs two US data centres, while also supplying the software talent that powers QFund, vCard, and the hospital platform.** - **Offshore delivery with onshore presence** - the business operates through a wholly-owned US subsidiary with a 75-person American team and a 150-person offshore team across two development centres in Hyderabad, using a mix of onsite, offshore, and hybrid models to serve clients. - **Two captive data centres as a foundation** - the company runs SOC-2-certified data centres in California and Atlanta that have provided co-located and managed hosting services for over 20 years, primarily to fintech, healthcare, and public-sector clients, with an uptime SLA of 99.995%. - **Complex work that resists commoditisation** - the division invests in areas like chatbots, machine learning, big-data analytics, and enterprise mobility, positioning itself in technology spaces that are less vulnerable to pricing pressure than standard IT services. - **The internal capability pool** - the mobility team has added capabilities in healthcare for vHealth, in fintech for vCard, and in consumer lending for QFund, meaning the services division doubles as the group’s shared technology backbone. # Group structure and partners **A web of wholly-owned subsidiaries holds each vertical, with the healthcare and US software businesses as the material entities, while a series of strategic agreements and warrant issues have brought in external capital and expertise.** - The two material subsidiaries are Virinchi Healthcare Pvt Ltd, which runs the hospital chain, and Ksoft Systems Inc, the US-based software-development and consulting arm. - A 51%-owned subsidiary, Asclepius Consulting & Technologies Pvt Ltd, provided the healthcare IT platform with a hospital-information-management system that enabled data-driven decision-making across the hospital network. - Virinchi Capital Private Limited, a wholly-owned fintech subsidiary, raised $2 million from eC Holdings Inc-a long-term QFund customer in the US-through compulsory convertible debentures to fund the mobile-driven credit-card business, with the investor gaining the right to appoint three of four directors upon conversion. - In February 2025, Virinchi Healthcare signed a 10-year strategic agreement with Health Care Services Pvt Ltd., that operates its clinical services under the brand name of TRUST Healthcare, led by the co-founder and former CEO of the CARE group of hospitals, to develop comprehensive cardiac services and advise on transforming Virinchi Hospitals into a model academic medical centre. - During FY26, the company issued several tranches of convertible equity warrants to public allottees, IT Peer Technologies LLC, and a promoter-group entity, with many of those warrants subsequently converted into equity shares between January and February 2026.

Documents — Virinchi Ltd

  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/js1n9na5txq63amyrnhkhgo6.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/w2sqk7jafsdm8tepf8jowv7w.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/kc1kebso58cytxhvw4o7m5mt.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/syje3pwd15dat5e0ku4au412.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/1u87b10dnwotzwzyto7omaph.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/31hm3ckqvzfm3vltbmtc0nds.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/8n9aky408xvysh8y0y2pnp47.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/54i3bum65qt58vucil2dh80z.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/ln4t85mqksoy28yofqu60uix.pdf
  • Q4 FY2023 Investor Presentation (Mar 2023, PDF): https://www.stockscans.in/document/jt1m4g71tfngc7zgesrg6c5f.pdf
  • Q2 FY2023 Investor Presentation (Sep 2022, PDF): https://www.stockscans.in/document/dwpgjjbujk4ww22smrf8e6dr.pdf
  • Q1 FY2023 Investor Presentation (Jun 2022, PDF): https://www.stockscans.in/document/xzuwxnvwv7g2u3fkwfzmncs1.pdf
  • Q3 FY2022 Investor Presentation (Dec 2021, PDF): https://www.stockscans.in/document/u9htoz5n8gyofahs7zbattte.pdf
  • Q2 FY2022 Investor Presentation (Sep 2021, PDF): https://www.stockscans.in/document/9fabfwlrx78zrnljv5xrfcb6.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/z4ma97s4hu9t8fcb0wa7d5if.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/we4se8hey887g2kihmhktve3.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/92vcatekxvopugx145uon1lz.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/a0o3pbya2tdvfozyui1i1dml.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/hjhllfjmma29e5q5ylhrcgha.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/ynj234hetdkod9482fr83z9s.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/98btcwoc430rb3ouy0o2w2zh.pdf